Advertisement
News
Advertisement

Boehringer Ingelheim expands capabilities in biopharmaceutical process science

Tue, 02/28/2012 - 11:25pm
Boehringer Ingelheim

Ingelheim, Germany, February 29, 2012 – Boehringer Ingelheim has expanded its biopharmaceutical development and manufacturing capabilities at its cell culture and microbial sites in Biberach, Germany and in Vienna, Austria. These expansions will enhance state-of-the art cell line development with the proprietary BI-HEX® high expression system and microbial strain as well as process development services for the contract manufacturing business. The investment of approximately 17 million Euros included the expansion of Boehringer Ingelheim’s current GMP (good manufacturing practice) cell banking, process science, cell line development and quality laboratories, all equipped with the latest technologies.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading